Body Composition, Sarcopenia, and Serum Myokines in Acromegaly: A Narrative Review

키워드

참고문헌 (60)

1. Daly AF, "The epidemiology of pituitary adenomas", Endocrinol Metab Clin North Am, 49, pp.347~355 (2020)[DOI]
2. Melmed S, "Pituitary-tumor endocrinopathies", N Engl J Med, 382, pp.937~950 (2020)[DOI]
3. Ritvonen E, "Mortality in acromegaly : a 20-year follow-up study", Endocr Relat Cancer, 23, pp.469~480 (2016)[DOI]
4. Dal J, "Cancer incidence in patients with acromegaly : a cohort study and meta-analysis of the literature", J Clin Endocrinol Metab, 103, pp.2182~2188 (2018)[DOI]
5. Melmed S, "Pathogenesis and diagnosis of growth hormone deficiency in adults", N Engl J Med, 380, pp.2551~2562 (2019)[DOI]
6. Ershadinia N, "Diagnosis and treatment of acromegaly : an update", Mayo Clin Proc, 97, pp.333~346 (2022)[DOI]
7. Giustina A, "Correction : consensus on criteria for acromegaly diagnosis and remission", Pituitary, 27, pp.88~ (2024)[DOI]
8. Young JA, "Musculoskeletal effects of altered GH action", Front Physiol, 13, pp.867921~ (2022)[DOI]
9. Escalada J, "Regulation of growth hormone(GH)gene expression and secretion during pregnancy and lactation in the rat : role of insulin-like growth factor-I, somatostatin, and GH-releasing hormone", Endocrinology, 138, pp.3435~3443 (1997)[DOI]
10. Clegg A, "Frailty and the endocrine system", Lancet Diabetes Endocrinol, 6, pp.743~752 (2018)[DOI]
11. Füchtbauer L, "Muscle strength in patients with acromegaly at diagnosis and during long-term follow-up", Eur J Endocrinol, 177, pp.217~226 (2017)[DOI]
12. Lopes AJ, "Explanatory models of muscle performance in acromegaly patients evaluated by knee isokinetic dynamometry : implications for rehabilitation", Hum Mov Sci, 49, pp.160~169 (2016)[DOI]
13. Homem TS, "Balance control and peripheral muscle function in aging : a comparison between individuals with acromegaly and healthy subjects", J Aging Phys Act, 25, pp.218~227 (2017)[DOI]
14. Haliloglu O, "Static and dynamic balances of patients with acromegaly and impact of exercise on balance", Pituitary, 22, pp.497~506 (2019)[DOI]
15. Gagliardi I, "Multidimensional geriatric evaluation in acromegaly : a comparative cross-sectional study", BMC Geriatr, 21, pp.598~ (2021)[DOI]
16. Sucunza N, "A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly", J Clin Endocrinol Metab, 94, pp.3889~3896 (2009)[DOI]
17. Reid TJ, "IGF-1 levels across the spectrum of normal to elevated in acromegaly : relationship to insulin sensitivity, markers of cardiovascular risk and body composition", Pituitary, 18, pp.808~819 (2015)[DOI]
18. Hansen TB, "Body composition in active acromegaly during treatment with octreotide : a double-blind, placebo-controlled cross-over study", Clin Endocrinol(Oxf), 41, pp.323~329 (1994)[DOI]
19. O'Sullivan AJ, "Body composition and energy expenditure in acromegaly", J Clin Endocrinol Metab, 78, pp.381~386 (1994)[DOI]
20. Wolf P, "Treatment of acromegaly has substantial effects on body composition : a long-term follow-up study", Eur J Endocrinol, 186, pp.173~181 (2021)[DOI]
21. Kaji H, "Bone metabolism and body composition in Japanese patients with active acromegaly", Clin Endocrinol(Oxf), 55, pp.175~181 (2001)[DOI]
22. Madeira M, "Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly", Osteoporos Int, 21, pp.2019~2025 (2010)[DOI]
23. Eroğlu I, "Osteosarcopenia in acromegaly : reduced muscle quality and increased vertebral fat deposition", J Endocrinol Invest, 46, pp.2573~2582 (2023)[DOI]
24. Gibney J, "Protein metabolism in acromegaly : differential effects of short-and long-term treatment", J Clin Endocrinol Metab, 92, pp.1479~1484 (2007)[DOI]
25. Arlien-Søborg MC, "Whole-body and forearm muscle protein metabolism in patients with acromegaly before and after treatment", J Clin Endocrinol Metab, 108, pp.e671~e678 (2023)[DOI]
26. Mizera Ł, "Myokines in acromegaly : an altered irisin profile", Front Endocrinol(Lausanne), 12, pp.728734~ (2021)[DOI]
27. Coskun M, "Assessment of forearm muscles with ultrasound shear wave elastography in patients with acromegaly", Pituitary, 26, pp.716~724 (2023)[DOI]
28. Tominaga A, "Effects of successful adenomectomy on body composition in acromegaly", Endocr J, 45, pp.335~342 (1998)[DOI]
29. Guo X, "Pre-and postoperative body composition and metabolic characteristics in patients with acromegaly : a prospective study", Int J Endocrinol, 2018, pp.4125013~ (2018)[DOI]
30. Hu HY, "Body composition assessed by bioelectrical impedance analysis(BIA)and the correlation with plasma insulin-like growth factor I(IGF-I)in normal Japanese subjects and patients with acromegaly and GH deficiency", Endocr J, 41, pp.63~69 (1994)[DOI]
31. Guedes da Silva DP, "On the functional capacity and quality of life of patients with acromegaly : are they candidates for rehabilitation programs?", J Phys Ther Sci, 25, pp.1497~1501 (2013)[DOI]
32. Lopes AJ, "What is the effect of peripheral muscle fatigue, pulmonary function, and body composition on functional exercise capacity in acromegalic patients?", J Phys Ther Sci, 27, pp.719~724 (2015)[DOI]
33. Hatipoglu E, "Acromegaly and aging : a comparative cross-sectional study", Growth Horm IGF Res, 25, pp.47~52 (2015)[DOI]
34. Zhang Y, "Neuromuscular blockade correlates with hormones and body composition in acromegaly", Int J Endocrinol, 2020, pp.2912839~ (2020)[DOI]
35. Sendur SN, "Reduced irisin levels in patients with acromegaly", Horm Mol Biol Clin Investig, 43, pp.251~261 (2022)[DOI]
36. Lima TRL, "Physical exercise improves functional capacity and quality of life in patients with acromegaly : a 12-week follow-up study", Endocrine, 66, pp.301~309 (2019)[DOI]
37. Brummer RJ, "Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1 year after adenomectomy", Eur J Clin Invest, 23, pp.199~205 (1993)[DOI]
38. Freda PU, "Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly", J Clin Endocrinol Metab, 93, pp.2334~2343 (2008)[DOI]
39. Reyes-Vidal CM, "Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment", J Clin Endocrinol Metab, 100, pp.2946~2955 (2015)[DOI]
40. Bredella MA, "Body composition and ectopic lipid changes with biochemical control of acromegaly", J Clin Endocrinol Metab, 102, pp.4218~4225 (2017)[DOI]
41. Kuker AP, "Long-term outcome of body composition, ectopic lipid, and insulin resistance changes with surgical treatment of acromegaly", J Endocr Soc, 7, pp.bvad028~ (2023)[DOI]
42. Freda PU, "Skeletal muscle mass in acromegaly assessed by magnetic resonance imaging and dual-photon x-ray absorptiometry", J Clin Endocrinol Metab, 94, pp.2880~2886 (2009)[DOI]
43. Kuker AP, "Body composition changes with long-term pegvisomant therapy of acromegaly", J Endocr Soc, 5, pp.bvab004~ (2021)[DOI]
44. Lopes AA, "Body composition in acromegaly according to disease activity-performance of dual X-ray absorptiometry and multifrequency bioelectrical impedance analysis", Front Endocrinol(Lausanne), 13, pp.866099~ (2022)[DOI]
45. Atmaca A, "Assessment of balance performance and fear of falling in acromegalic patients : a comparative study", J Endocrinol Invest, 36, pp.759~763 (2013)[DOI]
46. Lopes AJ, "Posture and balance control in patients with acromegaly : results of a cross-sectional study", Gait Posture, 40, pp.154~159 (2014)[DOI]
47. Thomas SG, "Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess", Clin Endocrinol(Oxf), 56, pp.351~358 (2002)[DOI]
48. Miller A, "Impact of musculoskeletal disease on quality of life in long-standing acromegaly", Eur J Endocrinol, 158, pp.587~593 (2008)[DOI]
49. Milioto A, "Skeletal muscle evaluation in patients with acromegaly", J Endocr Soc, 8, pp.bvae032~ (2024)[DOI]
50. Chen LY, "Association among serum insulin-like growth factor-1, frailty, muscle mass, bone mineral density, and physical performance among community-dwelling middle-aged and older adults in Taiwan", Rejuvenation Res, 21, pp.270~277 (2018)[DOI]
51. Bian A, "Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly", BMC Musculoskelet Disord, 21, pp.214~ (2020)[DOI]
52. Pedersen BK, "Muscles, exercise and obesity : skeletal muscle as a secretory organ", Nat Rev Endocrinol, 8, pp.457~465 (2012)[DOI]
53. Boström P, "A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis", Nature, 481, pp.463~468 (2012)[DOI]
54. Xin C, "Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway", Int J Obes(Lond), 40, pp.443~451 (2016)[DOI]
55. Lee HJ, "Irisin, a novel myokine, regulates glucose uptake in skeletal muscle cells via AMPK", Mol Endocrinol, 29, pp.873~881 (2015)[DOI]
56. Hittel DS, "Myostatin decreases with aerobic exercise and associates with insulin resistance", Med Sci Sports Exerc, 42, pp.2023~2029 (2010)[DOI]
57. Guo T, "Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity", PLoS One, 4, pp.e4937~ (2009)[DOI]
58. Dong J, "Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues", Int J Obes(Lond), 40, pp.434~442 (2016)[DOI]
59. Capaldo B, "Muscle sympathetic nerve activity in patients with acromegaly", J Clin Endocrinol Metab, 85, pp.3203~3207 (2000)[DOI]
60. Samuel VT, "Mechanisms for insulin resistance : common threads and missing links", Cell, 148, pp.852~871 (2012)[DOI]

관련 논문AI추천